集中化学療法を受けることができない成人の急性骨髄性白血病(AML)を治療するためのアザシチジンと組み合わせたペボネディスタットおよびベネトクラクスの研究 (PEVENAZA)
集中化学療法に適さない新たに診断された急性骨髄性白血病の成人におけるペボネディスタット、ベネトクラクス、およびアザシチジン対ベネトクラクスとアザシチジンの無作為化、非盲検、対照、第2相試験
The main aim is to see how the combination of pevonedistat + venetoclax + azacitidine compares to venetoclax + azacitidine in adults recently diagnosed with AML who are unable to be treated with intensive chemotherapy.
Participants will receive either pevonedistat + venetoclax + azacitidine or venetoclax + azacitidine in 28-day treatment cycles. Bone marrow samples (biopsy) will be collected throughout the study. Pevonedistat will be given as an intravenous (IV) infusion and Azacitidine will be given through IV or subcutaneous (under the skin).
Study treatments may continue as long as the participant is receiving benefit from it. Participants may choose to stop treatment at any time.
調査の概要
詳細な説明
The drug being tested in this study is called Pevonedistat. Pevonedistat is being tested to treat people who have AML. This study will compare the improvement in EFS in Arm A: Pevonedistat + Venetoclax + Azacitidine combination arm group when compared with Arm B: Venetoclax + Azacitidine.
The study will enroll approximately 164 participants. Participants will be randomly assigned in 1:1 ratio to one of the two treatment groups in 28-day treatment cycles and which will remain disclosed to the participant and study doctor during the study:
- Pevonedistat 20 mg/m^2 + Venetoclax 400 mg (ramp-up dose, Cycle 1 only: 100-400mg) + Azacitidine 75 mg/m^2
- Venetoclax 400 mg (ramp-up dose, Cycle 1 only: 100-400 mg) + Azacitidine 75 mg/m^2
This multi-center trial will be conducted worldwide. The overall time to participate in this study is approximately 3 years. Participants will attend the end-of-treatment visit 30 days after the last dose of study drug or before the start of subsequent anti-neoplastic therapy if that occurs sooner.
研究の種類
入学 (実際)
段階
- フェーズ2
連絡先と場所
研究場所
-
-
Arizona
-
Gilbert、Arizona、アメリカ、85234
- Banner MD Anderson Cancer Center
-
-
California
-
La Jolla、California、アメリカ、92093
- UC San Diego Moores Cancer Center
-
Orange、California、アメリカ、92868
- UC Irvine Medical Center
-
-
Florida
-
Miami、Florida、アメリカ、33136
- University of Miami Miller School of Medicine
-
Orlando、Florida、アメリカ、32804
- AdventHealth (Florida Hospital) - Transplant Institute
-
-
Kentucky
-
Louisville、Kentucky、アメリカ、40207
- Norton Cancer Institute - Suburban
-
-
Louisiana
-
New Orleans、Louisiana、アメリカ、70112
- Tulane Medical Center
-
-
Massachusetts
-
Boston、Massachusetts、アメリカ、02114
- Massachusetts General Hospital
-
-
Missouri
-
Kansas City、Missouri、アメリカ、64132
- HCA Midwest Health - SCRI - PPDS
-
-
New York
-
Lake Success、New York、アメリカ、11042
- Northwell Health Cancer Institute
-
New York、New York、アメリカ、10029-6574
- Icahn School of Medicine at Mount Sinai
-
Stony Brook、New York、アメリカ、11794
- Stony Brook Medicine
-
-
North Carolina
-
Chapel Hill、North Carolina、アメリカ、27514-4221
- University of North Carolina at Chapel Hill
-
-
Ohio
-
Cleveland、Ohio、アメリカ、44106
- University Hospitals Cleveland Medical Center
-
-
Oklahoma
-
Oklahoma City、Oklahoma、アメリカ、73104
- The University of Oklahoma Health Sciences Center
-
-
Rhode Island
-
Providence、Rhode Island、アメリカ、02903
- Rhode Island Hospital
-
-
South Dakota
-
Sioux Falls、South Dakota、アメリカ、57105
- Avera Cancer Institute
-
-
Texas
-
Houston、Texas、アメリカ、77030
- Houston Methodist Cancer Center
-
Lubbock、Texas、アメリカ、79410
- Joe Arrington Cancer Research and Treatment Center
-
-
Utah
-
Salt Lake City、Utah、アメリカ、84143
- Intermountain LDS Hospital
-
-
Virginia
-
Charlottesville、Virginia、アメリカ、22908
- University of Virginia Health System
-
-
West Virginia
-
Morgantown、West Virginia、アメリカ、26506
- West Virginia University Hospital
-
-
Wisconsin
-
Milwaukee、Wisconsin、アメリカ、53226
- Medical College of Wisconsin
-
-
-
-
-
Bologna、イタリア、40138
- Azienda Ospedaliero Universitaria Di Bologna - Policlinico S Orsola Malpighi
-
Florence、イタリア、50134
- Azienda Ospedaliera Universitaria Careggi
-
Pavia、イタリア、27100
- Fondazione IRCCS Policlinico San Matteo di Pavia
-
-
Calabria
-
Reggio Calabria、Calabria、イタリア、89133
- Grande Ospedale Metropolitano Bianchi-Melacrino-Morelli
-
-
Lombardy
-
Monza、Lombardy、イタリア、20900
- ASST di Monza - Azienda Ospedaliera San Gerardo
-
-
Milano
-
Rozzano、Milano、イタリア、20089
- Istituto Clinico Humanitas
-
-
Piedmont
-
Orbassano、Piedmont、イタリア、10043
- Azienda Sanitaria Ospedaliera S Luigi Gonzaga
-
Turin、Piedmont、イタリア、10126
- Azienda Ospedaliera Citta della Salute e della Scienza di Torino
-
-
Umbria
-
Perugia、Umbria、イタリア、06156
- Ospedale Santa Maria Della Misericordia Di Perugia
-
-
-
-
Alberta
-
Calgary、Alberta、カナダ、T2N 4N2
- Tom Baker Cancer Centre
-
Edmonton、Alberta、カナダ、T6G 2G3
- University of Alberta
-
-
Ontario
-
London、Ontario、カナダ、N6A 5W9
- London Health Sciences Centre
-
Ottawa、Ontario、カナダ、K1H 8L6
- Ottawa Hospital
-
-
Quebec
-
Québec、Quebec、カナダ、G1J 1Z4
- Hopital de L'enfant Jesus
-
-
-
-
-
Bobigny、フランス、93009
- Hopital Avicenne
-
Caen、フランス、14033
- Institut dHematologie de Basse Normandie
-
Grenoble、フランス、38043
- CHU de Grenoble
-
Lille、フランス、59037
- CHRU Lille
-
Nantes、フランス、44093
- CHRU Nantes
-
Nice、フランス、06202
- CHU de Nice
-
Paris、フランス、75012
- Hopital Saint Antoine
-
Paris、フランス、75475
- Hopital Saint Louis
-
Pierre-Bénite、フランス、69495
- Centre Hospitalier Lyon Sud
-
Poitiers、フランス、86021
- CHRU de Poitiers La Miletrie
-
Toulouse、フランス、31059
- EDOG - Institut Claudius Regaud - PPDS
-
-
Sarthe
-
Le Mans、Sarthe、フランス、72000
- Centre Hospitalier Le Mans
-
-
-
-
-
Bydgoszcz、ポーランド、85-168
- Szpital Uniwersytecki Nr 2 im. Dr Jana Biziela w Bydgoszczy
-
Gdansk、ポーランド、80-952
- Uniwersyteckie Centrum Kliniczne
-
Lublin、ポーランド、20-081
- Samodzielny Publiczny Szpital Kliniczny nr 1 w Lublinie
-
-
Lesser Poland Voivodeship
-
Krakow、Lesser Poland Voivodeship、ポーランド、31-501
- Szpital Uniwersytecki w Krakowie
-
-
Masovian Voivodeship
-
Warsaw、Masovian Voivodeship、ポーランド、02-776
- Instytut Hematologii i Transfuzjologii
-
Warsaw、Masovian Voivodeship、ポーランド、02-106
- MTZ Clinical Research Sp z o o
-
-
Podlaskie Voivodeship
-
Bialystok、Podlaskie Voivodeship、ポーランド、15-276
- Uniwersytecki Szpital Kliniczny w Bialymstoku
-
-
Łódź Voivodeship
-
Lodz、Łódź Voivodeship、ポーランド、93-513
- Wojewodzkie Wielospecjalistyczne Centrum Onkologii i Traumatologii im. M. Kopernika w Lodzi
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
-
Has morphologically confirmed diagnosis of AML (World Health Organization [WHO] criteria 2008). Participants may have newly diagnosed primary de novo AML or secondary AML (sAML), defined as AML after myelodysplastic syndromes (MDS) or myeloproliferative neoplasm (MPN), or therapy-related AML (t-AML) following cytotoxic therapy, and/or radiotherapy for a malignant or nonmalignant disease.
-
Is unfit for treatment with a standard arabinosylcytosine (Ara-C) and anthracycline induction regimen due to age or co-morbidities defined by 1 of the following:
- ≥75 years of age. OR
- ≥18 to <75 years of age with at least one of the following:
-
Eastern Cooperative Oncology Group (ECOG) performance status of 2 or 3.
-
Severe cardiac disorder (e.g., congestive heart failure requiring treatment, ejection fraction ≤50%, or chronic stable angina).
-
Severe pulmonary disorder (e.g., carbon monoxide lung diffusion capacity ≤65% or forced expiratory volume in 1 second ≤65%).
-
Creatinine clearance (CrCl) <45 mL/min (but ≥30 mL/min as part of general eligibility criteria).
-
Hepatic disorder with total bilirubin >1.5 times the upper limit of the normal range (ULN).
-
Has clinical laboratory values within the following parameters (repeat within 3 days before the first dose of study drug if laboratory values used for randomization were obtained more than 3 days before the first dose of study drug):
- Total bilirubin ≤1.5 times the ULN except in participants with Gilbert's syndrome. Participants with Gilbert's syndrome may enroll with direct bilirubin ≤3 times the ULN of the direct bilirubin. Elevated indirect bilirubin due to posttransfusion hemolysis is allowed.
- Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤3.0 times the ULN.
- Creatinine clearance (CrCl) ≥30 mL/min (calculated by the Modification of Diet in Renal Disease [MDRD] Study equation).
- Albumin >2.7 g/dL.
-
White blood cell (WBC) count <25 × 10^9/L. Participants who are cytoreduced with leukapheresis or with hydroxyurea may be enrolled if they meet the eligibility criteria before starting therapy.
Exclusion Criteria:
-
Has history of MPN with BCR-ABL1 translocation or AML with BCR-ABL1 translocation.
-
Has genetic diagnosis of acute promyelocytic leukemia.
-
Is eligible for intensive chemotherapy and/or allogeneic stem cell transplantation.
-
Has extramedullary AML without evidence of bone marrow involvement.
-
Had prior treatment with hypomethylating agents for AML (hypomethylating agent treatment for prior MDS is not exclusionary).
-
Has clinical evidence of or history of central nervous system involvement by AML.
-
Had diagnosed or treated for another malignancy (except for adequately treated carcinoma in situ of any organ or nonmelanoma skin cancer) within 1 year before randomization or previously diagnosed with another malignancy and have any evidence of residual disease that may compromise the administration of pevonedistat, venetoclax or azacitidine. Prior MDS is also allowed, but the participant cannot have received treatment for MDS within 14 days before first dose of any study drug.
-
Has a WBC count ≥25 × 10^9/L
-
Has uncontrolled human immunodeficiency virus (HIV) infection. Note: Known HIV positive participants who meet the following criteria will be considered eligible:
- Cluster difference 4 (CD4) count >350 cells/mm^3.
- Undetectable viral load.
- Maintained on modern therapeutic regimens utilizing non-cytochrome P (CYP)-interactive agents.
- No history of acquired immune deficiency syndrome (AIDS)-defining opportunistic infections.
-
Participant is known to be positive for hepatitis B or C infection, with the exception of those with an undetectable viral load within 3 months (hepatitis B or C testing is not required for eligibility assessment).
-
Has hepatic cirrhosis.
-
Has uncontrolled coagulopathy or bleeding disorder.
-
Has high blood pressure which cannot be controlled by standard treatments.
-
Has prolonged rate QTc interval ≥500 msec, calculated according to institutional guidelines.
-
Has left ventricular ejection fraction (LVEF) <40%, based on echocardiogram or multi gated acquisition (MUGA) scan at screening (data to be available within last 3 months of screening).
-
As infection is a common feature of AML, participants with active infection are permitted to enroll provided that the infection is under control and no signs of systemic inflammatory response beyond low grade fever that makes participant clinically unstable in the opinion of the investigator. Participants with uncontrolled infection shall not be enrolled until infection is treated and brought under control.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
アクティブコンパレータ:Venetoclax + Azacitidine
Participants received venetoclax 100 milligram (mg) tablet orally on Day 1; 200 mg on Day 2; thereafter, at 400 mg on Days 3 through 28 in Cycle 1 (cycle length= 28 days) and 400 mg on Days 1 through 28 in Cycle 2 and beyond if tolerated. Following the confirmation of remission in Cycle 1 or thereafter, venetoclax 400 mg was administered on Days 1 through 21 or 28 as per Investigator's discretion. In addition, participants received azacitidine 75 milligrams per square meter (mg/m^2) intravenous (IV) or subcutaneous (SC) dosing on Days 1 through 7 or Days 1 through 5, 8, and 9 in each cycle. |
Venetoclax tablets. Azacitidine IV or SC injection. |
|
実験的:Pevonedistat + Venetoclax + Azacitidine
Participants received pevonedistat 20 mg/m^2 as a 60-minute IV infusion on Days 1, 3, and 5 in each 28-day cycle. In addition participants received venetoclax 100 mg tablet orally on Day 1; 200 mg on Day 2; thereafter, at 400 mg on Days 3 through 28 in Cycle 1 (cycle length= 28 days) and 400 mg on Days 1 through 28 in Cycle 2 and beyond if tolerated. Following the confirmation of remission in Cycle 1 or thereafter, venetoclax 400 mg was administered on Day 1 through 21 or 28 as per Investigator's discretion. Participants also received azacitidine 75 mg/m^2 IV or SC dosing on Days 1 through 7 or Days 1 through 5, 8, and 9 in each cycle. |
Venetoclax tablets. Azacitidine IV or SC injection. Pevonedistat IV infusion.
他の名前:
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Event-Free Survival (EFS)
時間枠:Up to 22 months
|
EFS was defined as time from study randomization to date of failure to achieve complete remission (CR)/CR with incomplete blood count recovery (CRi), relapse from CR/CRi, or death. Assessments of disease response based on criteria: European Leukemia Net (ELN) 2017 guidelines. CR was defined as bone marrow blasts <5 percent (%); absence of circulating blasts and blasts with Auer rods; absence of extramedullary disease; absolute neutrophil count (ANC) greater than or equal to (≥) 1.0×10^9 per liter (10^9/L) (1000/microliter [µL]); platelet count≥100×10^9/L (100,000/µL). CRi was defined as all CR criteria except for residual neutropenia (<1.0×10^9/L [1000/µL]) or thrombocytopenia (<100×10^9/L [100,000/µL]). For participants who achieved CR/CRi, if relapse was not observed by time of analysis, data was censored at the date of last disease assessment. If failed to achieve CR/CRi, date of treatment failure was set on day of randomization. |
Up to 22 months
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Overall Survival (OS)
時間枠:Up to 36 months
|
OS was defined as the time from randomization to death from any cause. Participants without documentation of death at the time of analysis were censored at the date last known to be alive. OS was analyzed using the Kaplan-Meier method. |
Up to 36 months
|
|
30-Day Mortality Rate
時間枠:Day 30
|
30-day mortality rate was defined as the percentage of participants who survived at most 30 days from the first dose of study drug. |
Day 30
|
|
60-Day Mortality Rate
時間枠:Day 60
|
60-day mortality rate was defined as the percentage of participants who survived at most 60 days from the first dose of study drug. |
Day 60
|
|
Percentage of Participants With Complete Remission (CR)
時間枠:Up to 36 months
|
CR rate was defined as the percentage of participants who achieved the CR as evaluated by the investigator. Assessments of disease response were based on the criteria outlined in the ELN 2017 guidelines. CR was defined as bone marrow blasts <5%; absence of circulating blasts and blasts with Auer rods; absence of extramedullary disease; ANC≥1.0×10^9/L (1000/µL); platelet count≥100×10^9/L (100,000/µL). |
Up to 36 months
|
|
Percentage of Participants With Composite Complete Remission (CCR)
時間枠:Up to 36 months
|
CCR rate was defined as the percentage of participants who achieved the CR + CRi as evaluated by the investigator. Assessments of disease response were based on the criteria outlined in the ELN 2017 guidelines. CR was defined as bone marrow blasts <5%; absence of circulating blasts and blasts with Auer rods; absence of extramedullary disease; ANC≥1.0×10^9/L (1000/µL); platelet count≥100×10^9/L (100,000/µL). CRi was defined as all CR criteria except for residual neutropenia (<1.0×10^9/L [1000/µL]) or thrombocytopenia (<100×10^9/L [100,000/µL]). |
Up to 36 months
|
|
Overall Response Rate (ORR)
時間枠:Up to 36 months
|
ORR was defined as the percentage of participants who achieved the CR + CRi + Partial Remission (PR) as evaluated by the investigator. Assessments of disease response were based on the criteria outlined in the ELN 2017 guidelines. CR was defined as bone marrow blasts <5%; absence of circulating blasts and blasts with Auer rods; absence of extramedullary disease; ANC≥1.0×10^9/L (1000/µL); platelet count≥100×10^9/L (100,000/µL). CRi was defined as all CR criteria except for residual neutropenia (<1.0×10^9/L [1000/µL]) or thrombocytopenia (<100×10^9/L [100,000/µL]). PR was defined as all hematologic criteria of CR; decrease of bone marrow blast percentage to 5% to 25%; and decrease of pretreatment bone marrow blast percentage by at least 50%. |
Up to 36 months
|
|
Percentage of Participants With CR + CRh
時間枠:Up to 36 months
|
CR + CRh rate was defined as the percentage of participants who achieved the CR + CRh as evaluated by the investigator. Assessments of disease response were based on the criteria outlined in the ELN 2017 guidelines. CR was defined as bone marrow blasts <5%; absence of circulating blasts and blasts with Auer rods; absence of extramedullary disease; ANC≥1.0×10^9/L (1000/µL); platelet count≥100×10^9/L (100,000/µL). CRh was defined as bone marrow with <5% blasts, peripheral blood neutrophil count >0.5×10^3/µL and peripheral blood platelet count >0.5×10^5/µL. |
Up to 36 months
|
|
Percentage of Participants With Leukemia Response
時間枠:Up to 36 months
|
Leukemia response rate was defined as the percentage of participants who achieved the CR + CRi + PR + morphological leukemia-free state [MLFS, marrow CR (mCR)]) as evaluated by the investigator. Assessments of disease response were based on the criteria outlined in the ELN 2017 guidelines. CR was defined as bone marrow blasts <5%; absence of circulating blasts and blasts with Auer rods; absence of extramedullary disease; ANC≥ 1.0×10^9/L (1000/µL); platelet count≥100×10^9/L (100,000/µL). CRi was defined as all CR criteria except for residual neutropenia (<1.0×10^9/L [1000/µL]) or thrombocytopenia (<100×10^9/L [100,000/µL]). PR was defined as all hematologic criteria of CR; decrease of bone marrow blast percentage to 5% to 25%; and decrease of pretreatment bone marrow blast percentage by at least 50%. MLFS is defined as bone marrow blasts <5%; absence of blasts with Auer rods; absence of extramedullary disease; no hematologic recovery required. |
Up to 36 months
|
|
Duration of CR and CRi
時間枠:Up to 36 months
|
Duration of CR and CRi was defined as the time from first documentation of CR or CRi to the date of first documentation of progressive disease (PD) or relapse from CR or CRi, and was summarized descriptively using the Kaplan Meier method based on the responders. Assessments of disease response were based on the criteria outlined in the ELN 2017 guidelines. CR was defined as bone marrow blasts <5%; absence of circulating blasts and blasts with Auer rods; absence of extramedullary disease; ANC≥ 1.0×10^9/L (1000/µL); platelet count≥100×10^9/L (100,000/µL). CRi was defined as all CR criteria except for residual neutropenia (<1.0×10^9/L [1000/µL]) or thrombocytopenia (<100×10^9/L [100,000/µL]). |
Up to 36 months
|
|
Time to First CR, CRi and PR
時間枠:Up to 36 months
|
Time to first CR, CRi, and PR was defined as the time from randomization until the first documented CR, CRi or PR, whichever occurs first. Assessments of disease response were based on the criteria outlined in the ELN 2017 guidelines. CR was defined as bone marrow blasts <5%; absence of circulating blasts and blasts with Auer rods; absence of extramedullary disease; ANC≥ 1.0×10^9/L (1000/µL); platelet count≥100×10^9/L (100,000/µL). CRi was defined as all CR criteria except for residual neutropenia (<1.0×10^9/L [1000/µL]) or thrombocytopenia (<100×10^9/L [100,000/µL]). PR was defined as all hematologic criteria of CR; decrease of bone marrow blast percentage to 5% to 25%; and decrease of pretreatment bone marrow blast percentage by at least 50%. |
Up to 36 months
|
|
Plasma Concentration of Pevonedistat
時間枠:At multiple time points pre-dose and post-dose on Days 1, 3 and 5 in Cycle 1 and post-dose on Day 1 in Cycles 2 and 4 (cycle length= 28 days)
|
As pre-specified in the protocol, plasma concentration-time data were planned to contribute to future pharmacokinetic (PK) population and exposure response (safety/efficacy) analyses of pevonedistat. |
At multiple time points pre-dose and post-dose on Days 1, 3 and 5 in Cycle 1 and post-dose on Day 1 in Cycles 2 and 4 (cycle length= 28 days)
|
協力者と研究者
スポンサー
捜査官
- スタディディレクター:Medical Director、Takeda
出版物と役立つリンク
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (実際)
研究の完了 (実際)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
キーワード
追加の関連 MeSH 用語
その他の研究ID番号
- Pevonedistat-2002
- 2019-003117-33 (EudraCT番号)
- U1111-1239-7581 (レジストリ識別子:WHO)
- 2019 (米国 NIH グラント/契約)
- 2024-515424-36-00 (Ctis)
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.
IPD 共有アクセス基準
IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.
IPD 共有サポート情報タイプ
- STUDY_PROTOCOL
- SAP
- ICF
- CSR
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。